Beam Therapeutics Short Interest Ratio and Short Volume

-2.40 (-2.52 %)
(As of 07/23/2021 03:14 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume17,003 shs
Average Volume1.19 million shs
Market Capitalization$5.81 billion
P/E RatioN/A
Dividend YieldN/A

Beam Therapeutics (NASDAQ:BEAM) Short Interest Data

Current Short Volume5,340,000 shares
Previous Short Volume6,470,000 shares
Change Vs. Previous Month-17.47%
Dollar Volume Sold Short$687.31 million
Short Interest Ratio / Days to Cover5.8
Last Record DateJune, 30 2021
Outstanding Shares62,580,000 shares
Float Size44,400,000 shares
Short Percent of Float12.03%
Today's Trading Volume17,003 shares
Average Trading Volume1,194,319 shares
Today's Volume Vs. Average-98.58%

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Beam Therapeutics ?

Sign up to receive the latest short interest report for Beam Therapeutics and its competitors with MarketBeat's FREE newsletter.

Beam Therapeutics (NASDAQ:BEAM) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/20215,340,000 shares $687.31 million -17.5%12.0%5.8 $128.71
6/15/20216,470,000 shares $572.34 million -2.1%15.0%8.1 $88.46
5/28/20216,610,000 shares $517.10 million -4.1%15.3%7.8 $78.23
5/14/20216,890,000 shares $455.70 million +4.7%15.1%6.8 $66.14
4/30/20216,580,000 shares $513.90 million -5.9%14.5%6.3 $78.10
4/15/20216,990,000 shares $534.39 million +3.0%17.6%6.5 $76.45
3/31/20216,790,000 shares $514.41 million +0.3%18.1%6.1 $75.76
3/15/20216,770,000 shares $666.30 million +17.1%18.9%5.9 $98.42
2/26/20215,780,000 shares $511.65 million +8.2%17.7%5 $88.52
2/12/20215,340,000 shares $558.88 million -4.3%16.4%5.2 $104.66
1/29/20215,580,000 shares $557.39 million +0.9%17.1%5.9 $99.89
1/15/20215,530,000 shares $615.60 million No Change16.8%6.1 $111.32

Beam Therapeutics (NASDAQ:BEAM) Short Interest FAQ

speech bubbles
speech bubbles

What is Beam Therapeutics' current short interest?

Short interest is the volume of Beam Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 5,340,000 shares of BEAM short. 12.03% of Beam Therapeutics' shares are currently sold short. Learn More on Beam Therapeutics' current short interest.

What is a good short interest ratio for Beam Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Beam Therapeutics currently has a short interest ratio of 6.0. Learn More on a good short interest ratio for Beam Therapeutics

What is a good short interest percentage for Beam Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.03% of Beam Therapeutics' floating shares are currently sold short.

Is Beam Therapeutics' short interest increasing or decreasing?

Beam Therapeutics saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 5,340,000 shares, a decrease of 17.5% from the previous total of 6,470,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Beam Therapeutics' float size?

Beam Therapeutics currently has issued a total of 62,580,000 shares. Some of Beam Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Beam Therapeutics currently has a public float of 44,400,000 shares.

How does Beam Therapeutics' short interest compare to its competitors?

12.03% of Beam Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Beam Therapeutics: Bio-Techne Co. (1.14%), Novozymes A/S (0.00%), argenx SE (1.55%), Novavax, Inc. (8.28%), QIAGEN (1.96%), Repligen Co. (3.34%), Neurocrine Biosciences, Inc. (4.69%), CRISPR Therapeutics AG (5.04%), Fate Therapeutics, Inc. (13.44%), and Denali Therapeutics Inc. (6.54%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($8.32 billion), AstraZeneca PLC ($8.20 billion), Square, Inc. ($7.79 billion), Analog Devices, Inc. ($7.16 billion), S&P Global Inc. ($7.07 billion), Aon plc ($6.17 billion), Charter Communications, Inc. ($5.38 billion), Wayfair Inc. ($4.80 billion), AMC Entertainment Holdings, Inc. ($4.28 billion), and Snowflake Inc. ($3.19 billion). View all of the most shorted stocks.

What does it mean to sell short Beam Therapeutics stock?

Short selling BEAM is an investing strategy that aims to generate trading profit from Beam Therapeutics as its price is falling. Beam Therapeutics' stock is trading down $2.40 today. To short Beam Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Beam Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Beam Therapeutics?

A short squeeze for Beam Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BEAM, which in turn drives the price of the stock up even further.

How often is Beam Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BEAM, twice per month. The most recent reporting period available is June, 30 2021.

This page was last updated on 7/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.